Clinical Trials Browser

Lymphoma, Follicular, Recurrence

Leiomyosarcoma, Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Triple Negative Breast Neoplasms

Lymphoma, Large B-Cell, Diffuse

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

Neoplasm Metastasis, Uterine Neoplasms, Endometrial Neoplasms

Lymphoma, Large B-Cell, Diffuse

Resectable HER2-positive Breast Cancer

Endometrial Neoplasms

Breast Neoplasms

Lymphoma, Large B-Cell, Diffuse

Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Endometrial Neoplasms

Urinary Bladder Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

Lymphoma, Follicular, Recurrence

Lymphoma, Follicular

Endometrial Neoplasms

Hodgkin Disease, Lymphoma

Breast Neoplasms

HER2-positive Early Breast Cancer

Lymphoma, Large B-Cell, Diffuse

Lymphoma, Follicular, Recurrence

Lymphoma, Large B-Cell, Diffuse

Endometrial Neoplasms

Ovarian Neoplasms

Lymphoma, Follicular

Breast Neoplasms

Triple Negative Breast Neoplasms

Lymphoma, T-Cell, Peripheral

Lymphoma, Follicular

Lymphoma, T-Cell, Peripheral

Ovarian Neoplasms

Fallopian Tube Neoplasms, Ovarian Neoplasms

Leiomyosarcoma, Liposarcoma, Sarcoma, Histiocytoma, Malignant Fibrous

Breast Neoplasms

Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

Endometrial Neoplasms

Fallopian Tube Neoplasms, Ovarian Neoplasms

Lymphoma, Non-Hodgkin

Lymphoma, Non-Hodgkin

Breast Neoplasms

Ovarian Neoplasms

Breast Neoplasms

Neoplasm Metastasis, Sarcoma

Breast Neoplasms

Clinical Trials

LEDA

SaLuDo

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

MK-2140-010

EPCORE™FL-2

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

DEB

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

TroFuse-005

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

frontMIND

ESCALADE

Fern-EC-01

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

MK-3475-775

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

OLYMPIA-1

A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-Endometrial01)

A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

GOLSEEK-1

POLARIX

OLYMPIA-2

OLYMPIA-3

ASCENT-GYN-01

HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

APHINITY

MK-3475-522

CRESCENDO

ZUMA-22

Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer

ARTISTRY-7

ANNOUNCE

KEYNOTE-756

SELENE

A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

EPCORE DLBCL-2

Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer

JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer

CHRONOS-4

Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A

IMpassion050

SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

FeDeriCa

Phase 3 Study to Treat Patients With Soft Tissue Sarcomas

Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer

FIBROSARC